Zu Guo-Xiu, Tang Ji-Qin, Huang Hai-Liang, Han Tao
College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, Shandong Province, China.
School of Rehabilitation Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, Shandong Province, China.
World J Gastrointest Oncol. 2025 May 15;17(5):104737. doi: 10.4251/wjgo.v17.i5.104737.
In China Banxia Xiexin decoction (BXD) has been used in treating gastric cancer (GC) for thousands of years. BXD has been shown to reverse GC histopathology, but its chemical composition and action mechanism are still unknown.
To investigate the mechanism of BXD against GC based on utilizing transcriptomics and proteomics techniques experiments.
Using the AGS cell line as the model group, the Cell Counting Kit-8 method and Annexin V-AbFluor™ were employed 488/propidium iodide double staining method was used to detect the levels of cell proliferation and apoptosis. Differential expression genes and differentially expressed proteins before and after BXD intervention were detected using RNA-seq and Pro DIA techniques. Key transcription factors were identified by enrichment and analysis using Metascape, and the key pathways were validated by western blot and reverse transcription PCR and experiments.
BXD significantly inhibited the proliferation rate and migration rate of GC cells and promoted cell apoptosis. The comprehensive analysis of transcriptomics and proteomics showed that five transcription factors, namely phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, phosphoinositide-3-kinase regulatory subunit 1, AKT serine/threonine kinase 1, heat shock protein 90 alpha family class A member 1, and tumor protein p53, were key factors in BXD-mediated anti-cancer therapy and participated in the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. experiments were conducted using LY294002, an inhibitor of the PI3K/AKT signaling pathway, to validate the expression of five transcription factors at the protein and mRNA levels. experiments have shown that BXD inhibits tumor growth and suppresses the expression of the PI3K/AKT signaling pathway.
Transcriptomic and proteomic analysis showed that BXD inhibited tumor growth and slowed cancer progression by suppressing five factors in the PI3K/AKT signaling pathway, including phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, phosphoinositide-3-kinase regulatory subunit 1, and AKT serine/threonine kinase 1.
在中国，半夏泻心汤（BXD）用于治疗胃癌（GC）已有数千年历史。已证明BXD可逆转GC组织病理学，但其化学成分和作用机制仍不清楚。
基于转录组学和蛋白质组学技术实验研究BXD抗GC的机制。
以AGS细胞系作为模型组，采用细胞计数试剂盒-8法和Annexin V-AbFluor™ 488/碘化丙啶双染法检测细胞增殖和凋亡水平。采用RNA测序和蛋白质组数据独立分析（Pro DIA）技术检测BXD干预前后的差异表达基因和差异表达蛋白。使用Metascape通过富集和分析鉴定关键转录因子，并通过蛋白质印迹法和逆转录聚合酶链反应及实验验证关键通路。
BXD显著抑制GC细胞的增殖率和迁移率，并促进细胞凋亡。转录组学和蛋白质组学的综合分析表明，磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基α、磷脂酰肌醇-3-激酶调节亚基1、AKT丝氨酸/苏氨酸激酶1、热休克蛋白90α家族A类成员1和肿瘤蛋白p53这五个转录因子是BXD介导的抗癌治疗中的关键因素，并参与磷脂酰肌醇3-激酶（PI3K）/AKT信号通路。使用PI3K/AKT信号通路抑制剂LY294002进行实验，以验证五个转录因子在蛋白质和mRNA水平的表达。实验表明BXD抑制肿瘤生长并抑制PI3K/AKT信号通路的表达。
转录组学和蛋白质组学分析表明，BXD通过抑制PI3K/AKT信号通路中的五个因子，包括磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基α、磷脂酰肌醇-3-激酶调节亚基1和AKT丝氨酸/苏氨酸激酶1，抑制肿瘤生长并减缓癌症进展。
